SCHEMBL4720883

SCHEMBL4720883

CCOc1s[c]nc1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 1/20 0.40
SQOR Q9Y6N5 1/20 0.39
ALDH1A1 P00352 6/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 3/20 0.37
MAPK1 P28482 2/20 0.36
CACNA2D1 P54289 2/20 0.36
HSD17B10 Q99714 2/20 0.35
LMNA P02545 1/20 0.35
ATM Q13315 1/20 0.35
LTA4H P09960 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719956 0.87 SOAT1 (0.38) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL4724668 0.85 SOAT1 (0.43) ALDH1A1TP53MAPTMAPK1LTA4H
SCHEMBL468159 0.80 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL17625980 0.76 ALDH1A1 (0.50) TTKALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL2301856 0.73 ALDH1A1 (0.50) ALDH1A1HPGDKDM4EMAPTHSD17B10
SCHEMBL4720881 0.72 SQOR (0.39) TTKSQORALDH1A1SMN1; SMN2NPC1
SCHEMBL468074 0.72 DYRK1A (0.34)
SCHEMBL330385 0.70 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL17626024 0.70 MEN1 (0.47) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL15540493 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 TTK 3112/4885SQOR 644/4885ALDH1A1 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.